Metastatic Castration-resistant Prostate Cancer Clinical Trials in Tampa, Florida

8 studies are recruiting for metastatic castration-resistant prostate cancer in Tampa, Florida right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

   The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone).

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Moffitt Cancer Center, Tampa, Florida

   Locations

   155 in total

   Run by

   Amgen

   See if you can join NCT07213674 on ClinicalTrials.gov

2. A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

   Hormone therapy, or androgen deprivation therapy (ADT) is a standard way to treat prostate cancer. It works by reducing the amount of the main male sex hormone, testosterone in the body. Androgen receptor pathway inhibitors (ARPIs) are another type of hormone therapy. They either slow down how much…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   H. Lee Moffitt Cancer Center, Tampa, Florida

   Locations

   54 in total

   Run by

   Astellas Pharma Global Development, Inc.

   See if you can join NCT07005154 on ClinicalTrials.gov

3. A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

   The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in combination with enzalutamide, in patients with advanced solid t…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida

   Locations

   80 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT04104776 on ClinicalTrials.gov

4. A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer

   The primary purpose of this study is to evaluate the safety, tolerability, and efficacy of SYNC-T Therapy SV-102 and to identify the maximum tolerated dose (MTD) and/or selected dose for phase 2b study.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Moffitt Cancer Center, Tampa, Florida

   Locations

   23 in total

   Run by

   Syncromune, Inc.

   See if you can join NCT06533644 on ClinicalTrials.gov

5. Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC

   The purpose of this study is to evaluate whether high-dose testosterone followed by targeted radioligand therapy (TRT) is effective in treating metastatic castration resistant prostate cancer. Participants will be asked to spend about 6 months in this study. Participants will take study drug for 3.…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Moffitt Cancer Center, Tampa, Florida

   Run by

   H. Lee Moffitt Cancer Center and Research Institute

   See if you can join NCT07476001 on ClinicalTrials.gov

6. A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

   The main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, Tampa, Florida

   Locations

   16 in total

   Run by

   AstraZeneca

   See if you can join NCT06879041 on ClinicalTrials.gov

7. Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC

   This is a phase 1 single center clinical trial for patients with end stage Metastatic Castration Resistant Prostate Cancer who have progressed through standard of care treatment options and are on zoledronate for bone metastases. This clinical trial includes a dose-escalation phase and dose-expansi…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Moffitt Cancer Center, Tampa, Florida

   Run by

   H. Lee Moffitt Cancer Center and Research Institute

   See if you can join NCT06193486 on ClinicalTrials.gov

8. A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

   Medicines that reduce the amount of testosterone in the body are commonly used to treat prostate cancer. PRL-02 depot is a potential treatment for men with advanced prostate cancer. It is given by an injection into the muscle. Men with advanced prostate cancer can take part in this study. Their can…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Florida Urology Partners, Tampa, Florida

   Locations

   25 in total

   Run by

   Astellas Pharma Global Development, Inc.

   See if you can join NCT04729114 on ClinicalTrials.gov